Program
RPX7009
Also written as “RPX7009 and RPX2014”, “Meropenem plus vaborbactam” and “Combination RPX7009 and RPX2014”.
Its studies are mostly in Bacterial Infections · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 50 open or running | phase 1since Dec 13, 2012 | Dec 13, 2012 | none ahead |
| Menarini Group | 11 open or running | phase 2since Feb 3, 2025 | Feb 3, 2025 | Oct 2027phase 2 · NCT06828848 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 13, 2012First study: phase 1 study in Bacterial InfectionsNew to NovartisNovartis · NCT01751269 · 80 enrolled · Australia
- Jan 16, 2013Phase 1 study in Bacterial InfectionsNovartis · NCT01772836 · 30 enrolled · Australia
- Jul 9, 2013Phase 1 study in Bacterial InfectionsNovartis · NCT01897779 · 94 enrolled · Australia
- Dec 10, 2013Phase 1 study in Subjects With Varying Degrees of Renal Insufficiency andNovartis · NCT02020434 · 32 enrolled · United States
- Feb 14, 2014Phase 1 study in Healthy SubjectsNovartis · NCT02073812 · 26 enrolled · United States
- Feb 3, 2025Menarini Group's first study: phase 2 study in Gram Negative InfectionsNew to Menarini GroupMenarini Group · NCT06828848 · 44 planned · Czechia, France, Italy and more
- Oct 7, 2026Primary completion moved from 2026-07 to 2027-10Date moved laterphase 2 · +15 months · NCT06828848
Ahead
- Oct 2027Primary completion: phase 2 study in Gram Negative InfectionsMenarini Group · NCT06828848
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Carbepenem-hydrolyzing beta-lactamase KPC inhibitor”ChEMBL 37, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06828848Gram Negative Infections · Czechia, France, Italy and more | 2 | Recruiting | Menarini Group | Oct 2027 | 44 |
| NCT02073812Healthy Subjects · United States | 1 | Completed | Novartis | Apr 2014 | 26 |
| NCT02020434Subjects With Varying Degrees of Renal Insufficiency and · United States | 1 | Completed | Novartis | Sep 2014 | 32 |
| NCT01897779Bacterial Infections · Australia | 1 | Completed | Novartis | Feb 2014 | 94 |
| NCT01772836Bacterial Infections · Australia | 1 | Completed | Novartis | Mar 2013 | 30 |
| NCT01751269Bacterial Infections · Australia | 1 | Completed | Novartis | Jul 2013 | 80 |
How it is read
Names in the registry
- “RPX7009”, 3 entries
- “RPX7009 and RPX2014”, 2 entries
- “Meropenem plus vaborbactam”, 1 entry
- “Combination RPX7009 and RPX2014”, 1 entry
Codes read as this program: RPX7009.
Conditions, from the studies’ own filings
- Bacterial Infections, 3 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.